Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Abstract excerpt

The first step for the cure of multiple myeloma (MM) is to achieve a complete response (CR); 1 , 2 however, regardless of CR improvement, most patients experience disease progression or relapse in part due to the persistence of low levels of clonal plasma cells after treatment (minimal residual disease (MRD)). 3 In addition, many patients who achieve MRD-negative status also relapse, indicating that the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors